CureVac technologiesRNAs are essential, primordial biomolecules found in nature, a group of molecules that consists of many specialized members with different functions. mRNA has the ability to transmit genetic information, a key process in the development and evolution of living organisms and, thus, is one of the most important molecules for all forms of life. By utilizing its unique properties and overcoming its limitations such as instability, CureVac transforms mRNA into an entirely new class of therapeutic molecule with wide-ranging potential applications.
CureVac is combining both the antigenic and adjuvant properties of mRNAs to develop novel and effective mRNA vaccines. CureVac is currently developing therapeutic mRNA vaccines in oncology and therapeutic/prophylactic vaccines for infectious diseases.
CureVac’s RNAdjuvant® are modified, non-coding, long and complexed RNA molecules to increase the efficacy of a large number of different vaccines, including protein- and peptide-based vaccines without toxic effects.
CureVac’s in-house GMP facility allows for the simultaneous production of several RNA products in parallel. The production pace can easily be altered to meet market demands.
CureVac holds numerous patents and patent applications covering multiple aspects of its RNActive® and RNAdjuvant® technologies.